Figure 1. Change From Baseline In Monthly Migraine Days In Study 1 (Vyepti 1)
Vyepti Injection
Product Images NDC 67386-130
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Vyepti (NDC 67386-130). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Lundbeck Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 2. Distribution Of Change From Baseline In Mean Monthly Migraine Days Over Months 1 To 3 By Treatment Group In Study 1 (Vyepti 2)
This appears to be a table that shows the percentage of patients who experience fewer migraine days per month on placebo vs. two different doses of VYEPTI medication (100 mg quarterly and 300 mg quarterly). The table also displays the number of patients in each group (222 for placebo, and 221 and 222 for the two VYEPTI doses). There are also percentages displayed on the y-axis ranging from 10-30%, and a chart underneath that shows a decrease in migraine days over the course of the study.*
Figure 3. Percentage Of Patients With A Migraine From Day -1 (day Prior To Infusion) To Day 7 In Study 1 (Vyepti 3)
This is a chart depicting the percentage of patients with a migraine before and after infusion of different treatments. The treatments mentioned are VYEPTI 300 mg, VYEPTI 100 mg, and Placebo. The chart seems to indicate that VYEPTI 300 mg has a lower percentage of patients with a migraine compared to 100 mg and Placebo. The horizontal axis indicates the number of days post-infusion. Nonetheless, no information is provided regarding the overall efficacy of the treatments or the sample size used to generate these results.*
Figure 4. Change From Baseline In Monthly Migraine Days In Study 2 (Vyepti 4)
Figure 5. Distribution Of Change From Baseline In Mean Monthly Migraine Days Over Months 1-3 By Treatment Group In Study 2 (Vyepti 5)
This seems to be a chart showing the percentage of patients experiencing a reduction in migraine days per month while taking the medication VYEPTI 100mg or 300mg quarterly, compared to those taking a placebo. The chart also indicates that there were fewer migraine days in those taking VYEPTI, but no change or an increase in migraine days in some patients. The lower section of the chart includes dates and numbers that are difficult to interpret.*
Figure 6. Percentage Of Patients With A Migraine From Day -1 (day Prior To Infusion) To Day 7 In Study 2 (Vyepti 6)
This is a graph that shows the percentage of patients with a migraine (measured with standard error) on different days after infusion with either VYEPTI 300 mg, VYEPTI 100 mg or a placebo. The days range from 3 to 4.*
Lundbeck Logo 1 (Vyepti 7)
Lundbeck (Vyepti 8)
Ndc 67386-130-51 Vyeptitm (vye Ep' Tee) (eptinezumab-jjmr) Injection, For Intravenous Use 100 mg/ml Injection, For Intravenous Use 100 mg/ml (Vyepti 9)
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
